Shionogi, Inc

55 articles with Shionogi, Inc

• Shionogi Presents Real-World Evidence Showing Strong Efficacy with Fetroja® (cefiderocol) Against Treatment Resistant Bacterial Infections at IDWeek 2022

  10/19/2022

  Shionogi Presents Real-World Evidence Showing Strong Efficacy with Fetroja ® (cefiderocol) Against Treatment Resistant Bacterial Infections at IDWeek 2022.

• Shionogi Announces Strategic Re-Organization of U.S. Executive Leadership

  6/1/2022

  Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd. based in New Jersey, has announced a strategic executive leadership re-organization and expansion of the company’s Executive Committee with the following changes effective July 1, 2022:.

• New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance

  4/23/2022

  Shionogi & Co., Ltd. announced new results from two late-breaking presentations of S-217622 at the 32nd European Congress of Clinical Microbiology & Infectious Diseases in Lisbon, 23 – 26 April.

• ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

  9/29/2021

  ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, presented three-year results from the TANGO study at IDWeek 2021, being held virtually 29 September - 3 October.

• ViiV Healthcare announces exclusive license agreement with Shionogi to develop third-generation HIV integrase inhibitor with potential for ultra long-acting dosing intervals

  9/28/2021

  ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline, with Pfizer and Shionogi as shareholders, announced an exclusive collaboration and license agreement with Shionogi & Co. Ltd. for S-365598, a third-generation investigational integrase strand transfer inhibitor with potential for use in ultra long-acting HIV regimens.

• Shionogi Strengthens U.S. Executive Leadership Team to Support Growth

  5/3/2021

  Appoints Executive Vice President Nathan McCutcheon to the Role of Chief Operating Officer Names Senior Vice President Gianine Esposito to the Executive Committee

• 

  Clinical Catch-Up: March 8-12

  3/15/2021

  It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more.

• Shionogi Accelerates Development of Potential COVID-19 Treatments and Vaccine

  4/28/2020

  In response to the novel coronavirus (SARS-CoV-2), Shionogi & Co., Ltd. (hereafter “Shionogi”), a pharmaceutical company with a major focus on infectious diseases, has joined the ranks of pharmaceutical companies across the globe and is working with public institutions, academia and partner companies in the following efforts to fight against COVID-19: Commitment to the discovery of novel

• ViiV Healthcare and UNC-Chapel Hill announce five-year renewal of innovative HIV cure partnership

  3/9/2020

  Unique public-private collaboration provides continued funding for HIV Cure Center and Qura Therapeutics, the joint venture that brings academic and pharmaceutical research scientists together

• 

  Allergy Immunotherapy: Relief that is Nothing to Sneeze at

  2/27/2020

  *Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone -  over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...

• Shionogi’s FETROJA® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S.

  2/24/2020

  Feb. 24, 2020 12:58 UTC Shionogi’s FETROJA ® (cefiderocol) Now Available for the Treatment of Complicated Urinary Tract Infections in the U.S. OSAKA, Japan & FLORHAM PARK, N.J.--( BUSINESS WIRE )-- Shionogi & Co., Ltd. (hereafter “Shionogi”) today announced FETROJA ® (cefiderocol) is now available in the U.S. for patients 18 years of age or older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTIs), includ

• ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV

  12/21/2019

  ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter from the US Food and Drug Administration regarding its application for cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults..

• ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

  12/5/2019

  Fostemsavir is being developed for use in combination with other antiretroviral agents in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection who are unable to form a suppressive regimen due to resistance, intolerance or safety considerations.

• ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

  11/21/2019

  Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells.

• ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Use of Dovato in Virologically Suppressed Adults with HIV-1

  10/16/2019

  ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the submission of a supplemental New Drug Application to the US Food and Drug Administration for Dovato as a switch treatment for HIV-1 infection in virologically suppressed adults on a stable antiretroviral regimen with no treatment failure.

• Shionogi Announces Licensing of Symproic® (naldemedine) to BioDelivery Sciences International Inc.

  4/10/2019

  Shionogi Inc. announced that BioDelivery Sciences International, Inc., a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, has licensed full rights to commercialize Symproic® tablets 0.2 mg in the United States.

• Shionogi to Present Clinical Data on Lusutrombopag at the International Liver Congress™ 2019 of the European Association for the Study of the Liver (EASL)

  4/4/2019

  Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V., announced it will present four posters on lusutrombopag, a once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at The International Liver Congress™, the annual meeting of the European Association for the Study of the Liver (EASL), to be held in Vienna, Austria, April 10-14, 2019.

• ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 2018

  7/18/2018

  ViiV Healthcare with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands.

• Fifty-Two Week Safety Study on Symproic® (naldemedine) for Opioid-induced Constipation (OIC) in Adults with Chronic Non-cancer Pain Published in PAIN

  3/6/2018

  The study is the first to investigate a peripherally-acting mu-opioid receptor antagonist (PAMORA) over the course of 52 weeks in a randomized, placebo-controlled and double-blind manner.

• Shionogi And Purdue Pharma L.P. Announce U.S. Availability Of Symproic® (Naldemedine) For The Treatment Of Opioid-Induced Constipation In Adults With Chronic Non-Cancer Pain

  10/12/2017